Lisinopril | Silver gate Pharma | ||
1 mg/ml; Solution, Oral |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
None | ||
None | None | ||
Qbrelis is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure | |||
Yes
|
Qbrelis | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 |
---|---|---|---|---|---|---|---|---|
*** ****** | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* (***** ******) | *** ********* (***** ******) |
****** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
*** ****** | *** \ ********* | *** *, **** | ******* | **** | ******* *** **** *** *** **** |
****** ****** | ** \ ** | *** *, **** | ******* | **** | ******* *** **** *** *** **** |